Genetic Disorders of Bone or Osteodystrophies of Jaws—A Review

Abstract

Bone is a specialized form of connective tissue, which is mineralized and made up of approximately 28% type I collagen and 5% noncollagenous matrix proteins. The properties of bone are very remarkable, because it is a dynamic tissue, undergoing constant renewal in response to mechanical, nutritional, and hormonal influences. In 1978, “The International Nomenclature of Constitutional Diseases of Bone” divided bone disorders into two broad groups: osteochondrodysplasias and dysostoses. The osteochondrodysplasia group is further subdivided into two categories: dysplasias (abnormalities of bone and/or cartilage growth) and osteodystrophies (abnormalities of bone and/or cartilage texture). The dysplasias form the largest group of bone disorders, hence the loose term “skeletal dysplasia” that is often incorrectly used when referring to a condition that is in reality an osteodystrophy or dysostosis. The word “dystrophy” implies any condition of abnormal development. “Osteodystrophies,” as their name implies, are disturbances in the growth of bone. It is also known as osteodystrophia. It includes bone diseases that are neither inflammatory nor neoplastic but may be genetic, metabolic, or of unknown origin. Recent studies have shown that bone influences the activity of other organs, and the bone is also influenced by other organs and systems of the body, providing new insights and evidencing the complexity and dynamic nature of bone tissue. The 1,25-dihydroxyvitamin D3, or simply vitamin D, in association with other hormones and minerals, is responsible for mediating the intestinal absorption of calcium, which influences plasma calcium levels and bone metabolism. Diagnosis of the specific osteodystrophy type is a rather complex process and various biochemical markers and radiographic findings are used, so as to facilitate this condition. For diagnosis, we must consider the possibility of lesions related to bone metabolism altered by chronic renal failure (CRI), such as the different types of osteodystrophies, and differentiate from other possible neoplastic and/or inflammatory pathologies. It is important that the dentist must be aware of patients medical history, suffering from any systemic diseases, and identify the interference of the drugs and treatments to control them, so that we can able to perform the correct diagnosis and propose the most adequate treatment and outcomes of the individuals with bone lesions.

Keywords

PTH—Parathyroid hormone / CRI—Chronic renal failure / RANKL—Receptor activator of NF-B ligand / TGF—Transforming growth factor / M-CSF—Macrophage colony stimulating factor / FGFR3—Fibroblast growth factor receptor

References

[1] Clarke B.Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008;3(03, Suppl 3):S131-S139

[2] Downey PA, Siegel MI.Bone biology and the clinical implications for osteoporosis. Phys Ther 2006;86(01):77-91

[3] Ralston SH.Bone structure and metabolism. Medicine 2013;41(10):581-585

[4] Matsuo K, Irie N.Osteoclast-osteoblast communication. Arch Biochem Biophys 2008;473(02):201-209

[5] Shafer WG, Hine MK, Levy BM, et al. A Textbook of Oral Pathology. 4th ed. Philadelphia: Saunders; 2000:678-680

[6] Fukumoto S, Martin TJ.Bone as an endocrine organ. Trends Endocrinol Metab 2009;20(05):230-236

[7] Sims NA, Gooi JH.Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008;19(05):444-451

[8] Parfitt AM.Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002;30(01):5-7

[9] Roodman GD.Cell biology of the osteoclast. Exp Hematol 1999;27(08):1229-1241

[10] Blair HC, Athanasou NA.Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 2004;19(01):189-199

[11] Boskey AL, Spevak L, Paschalis E, Doty SB, McKee M D. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 2002;71(02):145-154

[12] Yagami K, Suh J-Y, Enomoto-Iwamoto M, et al. Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J Cell Biol 1999;147(05): 1097-1108

[13] Buckwalter JA, Glimcher MJ, Cooper RR, Recker R. Bone biology. I: Structure, blood supply, cells, matrix, and mineralization. Instr Course Lect 1996;45:371-386

[14] Zimmerman D, Jin F, Leboy P, Hardy S, Damsky C.Impaired bone formation in transgenic mice resulting from altered integrin function in osteoblasts. Dev Biol 2000;220(01):2-15

[15] Marie PJ.Role of N-cadherin in bone formation. J Cell Physiol 2002;190(03):297-305

[16] Helfrich MH, Stenbeck G, Nesbitt MA, et al. “Integrins and adhesion molecules.” In: JP Bilezikan, LG Raisz, TJ Martin, eds.Principles of Bone Biology. San Diego, Calif, USA: Academic Press, Elsevier; 2008:385-424

[17] Negishi-Koga T, Shinohara M, Komatsu N, et al.Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17(11):1473-1480

[18] Calvi LM, Sims NA, Hunzelman JL, et al.Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001;107(03):277-286

[19] Cenci S, Weitzmann MN, Roggia C, et al.Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106(10):1229-1237

[20] Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S.Genetic determinants of bone mass in adults. A twin study. J Clin Invest 1987;80(03):706-710

[21] Baljet B.Aspects of the history of osteogenesis imperfecta (Vrolik’s syndrome). Ann Anat 2002;184(01):1-7

[22] Martin A, Liu S, David V, et al.Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011;25(08):2551-2562

[23] Alharbi SA.A systematic overview of osteogenesis imperfecta. Mol Biol 2016;5:150

[24] Van Dijk FS, Sillence DO.Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 2014;164A(06):1470-1481

[25] Brusin JH. Osteogenesis imperfecta. Radiol Technol 2008;79(06): 535-548, quiz 549-551

[26] Monti E, Mottes M, Fraschini P, et al.Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 2010;6:367-381

[27] Pauli RM, Botto LD. Achondroplasia. In: Cassidy SB, Battaglia A, Carey J, Viskochil DH, eds. Management of Genetic Syndromes. 2021

[28] Choi DY, Toledo-Aral JJ, Lin HY, et al.Fibroblast growth factor receptor 3 induces gene expression primarily through Ras-independent signal transduction pathways. J Biol Chem 2001;276(07):5116-5122

[29] Nikkel SM, Major N, King WJ.Growth and development in thanatophoric dysplasia - an update 25 years later. Clin Case Rep 2013;1(02):75-78

[30] Gelb BD.Marfan's syndrome and related disorders-more tightly connected thanwe thought. N Engl JMed 2006;355(08):841-844

[31] Cañadas V, Vilacosta I, Bruna I, Fuster V.Marfan syndrome. Part 2: treatment and management of patients. Nat Rev Cardiol 2010;7(05):266-276

[32] Schulz A,Moushous D, Steward CG, Villa A, Sobacchi C. Osteopetrosis: consensus guidelines for diagnosis, therapy and followup. 2015. Doi: https://doi.org/10.1055/s-oo41-1724105

[33] Stark Z, Savarirayan R.Osteopetrosis. Orphanet J Rare Dis 2009;4:5

[34] Jayachandran S, Preethi M.Clinical spectrum of osteopetrosis with secondary osteomyelitis of the mandible: report of two cases. J Indian Acad Oral Med Radiol 2018;30:165-168

[35] Landa J, Margolis N, Di Cesare P.Orthopaedic management of the patient with osteopetrosis. J Am Acad Orthop Surg 2007;15(11): 654-662

[36] McNamara CM, O’Riordan BC, Blake M, Sandy JR. Cleidocranial dysplasia: radiological appearances on dental panoramic radiography. Dentomaxillofac Radiol 1999;28(02):89-97

[37] Whyte M.Hypophosphatasia. In: Glorieux FH, Pettifor JM, Juppner H, eds. Pediatric Bone: Biology and Diseases. San Diego, CA: Academic Press; 2012:771-794

[38] Fraser D, Yendt ER, Christie FH.Metabolic abnormalities in hypophosphatasia. Lancet 1955;268(6858):286

[39] Hofmann C, Girschick HJ, Mentrup B, et al.Clinical aspects of hypophosphatasia: an update. Clin Rev Bone Miner Metab 2013; 11(02):60-70

[40] Jones WA, Gerrie J, Pritchard J. Cherubism-familial fibrous dysplasia of the jaws. J Bone Joint Surg Br 1950;32-B(03):334-347

[41] Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ.Cherubism: best clinical practice. Orphanet J Rare Dis 2012;7(Suppl 1):S6

[42] Reitsma JH, Elmi P, Ongkosuwito EM, Buschang PH, Prahl-Andersen B.A longitudinal study of dental arch morphology in children with the syndrome of Crouzon or Apert. Eur J Oral Sci 2013;121(04):319-327

[43] Trainor PA, Dixon J, Dixon MJ.Treacher Collins syndrome: etiology, pathogenesis and prevention. Eur J Hum Genet 2009;17(03): 275-283

[44] Bellingham AJ, Heuhns ER.Compensation in haemolytic anaemia caused by abnormal haemoglobin. Nature Lancet 1968; 218:924-926

[45] Scott BR.Sickle cell anaemia. Paediatric Child of N Am 1962; 93:649

[46] Sankaran VG, Nathan DG.Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am 2010;24(06): 1005-1020

[47] Looser. Zun kenntis den osteogenesis Imperfecta congenita et Tarda (sogennate idiopathische osteopatyrosis) (in German). Mittlg Grenzgebiete MEd chir 1906;15:161-207

[48] Sykes B, Francis MJ, Smith R.Altered relation of two collagen types in osteogenesis imperfecta. N Engl J Med 1977;296:1200-1203

[49] Bradford WL, Dye J.Observations on the morphology of the crythmytes inMediterranean disease thalassemia (Erythroblastic anemia of cooley). J Pediatr 1936;9(03):12-13

RIGHTS & PERMISSIONS

2021 Global Medical Genetics